Brain Cancer - Pipeline Review, H2 2015

Published: Oct, 2015 | Pages: 311 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Brain Cancer - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Brain Cancer - Pipeline Review, H2 2015', provides an overview of the Brain Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Brain Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Brain Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Brain Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Brain Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Brain Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Brain Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Brain Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents
 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Brain Cancer Overview 10
Therapeutics Development 11
Pipeline Products for Brain Cancer - Overview 11
Pipeline Products for Brain Cancer - Comparative Analysis 12
Brain Cancer - Therapeutics under Development by Companies 13
Brain Cancer - Therapeutics under Investigation by Universities/Institutes 18
Brain Cancer - Pipeline Products Glance 19
Late Stage Products 19
Clinical Stage Products 20
Early Stage Products 21
Brain Cancer - Products under Development by Companies 22
Brain Cancer - Products under Investigation by Universities/Institutes 26
Brain Cancer - Companies Involved in Therapeutics Development 27
2-BBB Medicines BV 27
AbbVie Inc. 28
Actinium Pharmaceuticals, Inc. 29
AngioChem Inc. 30
Arrien Pharmaceuticals, LLC 31
BeiGene(Beijing) Co.,Ltd 32
Berg, LLC 33
biOasis Technologies Inc. 34
Boehringer Ingelheim GmbH 35
Bristol-Myers Squibb Company 36
Cavion LLC 37
Critical Outcome Technologies Inc. 38
CureFAKtor Pharmaceuticals, LLC 39
Diffusion Pharmaceuticals LLC 40
e-Therapeutics Plc 41
Exelixis, Inc. 42
F. Hoffmann-La Roche Ltd. 43
Hutchison MediPharma Limited 44
Komipharm International Co., Ltd. 45
Lipocure Ltd. 46
Medicenna Therapeutics, Inc 47
MEI Pharma, Inc. 48
NatureWise Biotech & Medicals Corporation 49
Nektar Therapeutics 50
Nerviano Medical Sciences S.r.l. 51
Novartis AG 52
Novogen Limited 53
Oncology Research International Limited 54
Oncolytics Biotech Inc. 55
Oncothyreon Inc. 56
Pfizer Inc. 57
Philogen S.p.A. 58
Phosplatin Therapeutics LLC 59
Prana Biotechnology Limited 60
Progenics Pharmaceuticals, Inc. 61
Puma Biotechnology, Inc. 62
Radius Health, Inc. 63
Sanofi 64
Spectrum Pharmaceuticals, Inc. 65
Stemline Therapeutics, Inc. 66
Takeda Pharmaceutical Company Limited 67
Tocagen Inc. 68
ViraTherapeutics GmbH 69
Zymeworks Inc. 70
Brain Cancer - Therapeutics Assessment 71
Assessment by Monotherapy Products 71
Assessment by Combination Products 72
Assessment by Target 73
Assessment by Mechanism of Action 77
Assessment by Route of Administration 80
Assessment by Molecule Type 82
Drug Profiles 84
(dabrafenib mesylate + trametinib dimethyl sulfoxide) - Drug Profile 84
(topotecan hydrochloride + vincristine sulfate) - Drug Profile 87
2B3-101 - Drug Profile 88
Actimab-Br - Drug Profile 90
afatinib dimaleate - Drug Profile 91
ANG-1005 - Drug Profile 95
ANG-4043 - Drug Profile 97
ARN-7016 - Drug Profile 98
BGBA-317 - Drug Profile 99
BT-2111 - Drug Profile 100
cabazitaxel - Drug Profile 101
cabozantinib s-malate - Drug Profile 103
Cell Therapy to Target CD133 for Refractory and Relapsed Malignancies - Drug Profile 107
ceritinib - Drug Profile 108
CFAKC-4 - Drug Profile 111
cobimetinib fumarate - Drug Profile 112
COTI-2 - Drug Profile 117
dacomitinib - Drug Profile 120
Dendritic Cell Therapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile 123
Edotreotide Labeled Yttrium 90 - Drug Profile 124
etirinotecan pegol - Drug Profile 126
ETS-2101 - Drug Profile 129
Gene Therapy for Brain Cancer - Drug Profile 131
HMPL-813 - Drug Profile 132
ipilimumab - Drug Profile 133
irbinitinib - Drug Profile 137
irinotecan hydrochloride + TBio-02 - Drug Profile 139
KML-001 - Drug Profile 141
LEQ-506 - Drug Profile 143
lorlatinib - Drug Profile 144
lucanthone hydrochloride - Drug Profile 146
MDNA-55 - Drug Profile 148
Monoclonal Antibody to Inhibit CD47 for Kidney Transplantation, Cardiovascular Disease and Oncology - Drug Profile 149
NBM-01 - Drug Profile 151
neratinib - Drug Profile 152
nimotuzumab - Drug Profile 157
NMSE-973 - Drug Profile 161
NOV-202 - Drug Profile 162
ORIL-007 - Drug Profile 163
PB-357 - Drug Profile 164
PBT-519 - Drug Profile 165
pelareorep - Drug Profile 166
pracinostat - Drug Profile 171
PT-112 - Drug Profile 173
RAD-1901 - Drug Profile 174
radretumab - Drug Profile 176
RRX-001 - Drug Profile 177
siomycin A - Drug Profile 179
SL-301 - Drug Profile 180
SL-302 - Drug Profile 181
Small Molecule for Brain Cancer and Malignant Glioma - Drug Profile 182
Small Molecule for Glioblastomas - Drug Profile 183
Small Molecule to Agonize GPR55 for Oncology - Drug Profile 184
Small Molecules to Inhibit Hedgehog Signaling for Medulloblastoma - Drug Profile 185
THR-317 - Drug Profile 186
TPI-287 - Drug Profile 188
transcrocetinate sodium - Drug Profile 190
Trilexium - Drug Profile 191
TTL-1177 - Drug Profile 192
ubidecarenone - Drug Profile 193
Vaccine for Cancer - Drug Profile 195
Vaccine for Glioblastoma Multiforme - Drug Profile 196
veliparib - Drug Profile 197
VMY-1103 - Drug Profile 201
vocimagene amiretrorepvec + flucytosine ER - Drug Profile 202
ZW-39 - Drug Profile 204
Brain Cancer - Recent Pipeline Updates 205
Brain Cancer - Dormant Projects 291
Brain Cancer - Discontinued Products 295
Brain Cancer - Product Development Milestones 296
Featured News & Press Releases 296
Appendix 305
Methodology 305
Coverage 305
Secondary Research 305
Primary Research 305
Expert Panel Validation 305
Contact Us 305
Disclaimer 306

List of Tables

Number of Products under Development for Brain Cancer, H2 2015 16
Number of Products under Development for Brain Cancer - Comparative Analysis, H2 2015 17
Number of Products under Development by Companies, H2 2015 19
Number of Products under Development by Companies, H2 2015 (Contd..1) 20
Number of Products under Development by Companies, H2 2015 (Contd..2) 21
Number of Products under Development by Companies, H2 2015 (Contd..3) 22
Number of Products under Investigation by Universities/Institutes, H2 2015 23
Comparative Analysis by Late Stage Development, H2 2015 24
Comparative Analysis by Clinical Stage Development, H2 2015 25
Comparative Analysis by Early Stage Development, H2 2015 26
Products under Development by Companies, H2 2015 27
Products under Development by Companies, H2 2015 (Contd..1) 28
Products under Development by Companies, H2 2015 (Contd..2) 29
Products under Development by Companies, H2 2015 (Contd..3) 30
Products under Investigation by Universities/Institutes, H2 2015 31
Brain Cancer - Pipeline by 2-BBB Medicines BV, H2 2015 32
Brain Cancer - Pipeline by AbbVie Inc., H2 2015 33
Brain Cancer - Pipeline by Actinium Pharmaceuticals, Inc., H2 2015 34
Brain Cancer - Pipeline by AngioChem Inc., H2 2015 35
Brain Cancer - Pipeline by Arrien Pharmaceuticals, LLC, H2 2015 36
Brain Cancer - Pipeline by BeiGene(Beijing) Co.,Ltd, H2 2015 37
Brain Cancer - Pipeline by Berg, LLC, H2 2015 38
Brain Cancer - Pipeline by biOasis Technologies Inc., H2 2015 39
Brain Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2015 40
Brain Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2015 41
Brain Cancer - Pipeline by Cavion LLC, H2 2015 42
Brain Cancer - Pipeline by Critical Outcome Technologies Inc., H2 2015 43
Brain Cancer - Pipeline by CureFAKtor Pharmaceuticals, LLC, H2 2015 44
Brain Cancer - Pipeline by Diffusion Pharmaceuticals LLC, H2 2015 45
Brain Cancer - Pipeline by e-Therapeutics Plc, H2 2015 46
Brain Cancer - Pipeline by Exelixis, Inc., H2 2015 47
Brain Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 48
Brain Cancer - Pipeline by Hutchison MediPharma Limited, H2 2015 49
Brain Cancer - Pipeline by Komipharm International Co., Ltd., H2 2015 50
Brain Cancer - Pipeline by Lipocure Ltd., H2 2015 51
Brain Cancer - Pipeline by Medicenna Therapeutics, Inc, H2 2015 52
Brain Cancer - Pipeline by MEI Pharma, Inc., H2 2015 53
Brain Cancer - Pipeline by NatureWise Biotech & Medicals Corporation, H2 2015 54
Brain Cancer - Pipeline by Nektar Therapeutics, H2 2015 55
Brain Cancer - Pipeline by Nerviano Medical Sciences S.r.l., H2 2015 56
Brain Cancer - Pipeline by Novartis AG, H2 2015 57
Brain Cancer - Pipeline by Novogen Limited, H2 2015 58
Brain Cancer - Pipeline by Oncology Research International Limited, H2 2015 59
Brain Cancer - Pipeline by Oncolytics Biotech Inc., H2 2015 60
Brain Cancer - Pipeline by Oncothyreon Inc., H2 2015 61
Brain Cancer - Pipeline by Pfizer Inc., H2 2015 62
Brain Cancer - Pipeline by Philogen S.p.A., H2 2015 63
Brain Cancer - Pipeline by Phosplatin Therapeutics LLC, H2 2015 64
Brain Cancer - Pipeline by Prana Biotechnology Limited, H2 2015 65
Brain Cancer - Pipeline by Progenics Pharmaceuticals, Inc., H2 2015 66
Brain Cancer - Pipeline by Puma Biotechnology, Inc., H2 2015 67
Brain Cancer - Pipeline by Radius Health, Inc., H2 2015 68
Brain Cancer - Pipeline by Sanofi, H2 2015 69
Brain Cancer - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2015 70
Brain Cancer - Pipeline by Stemline Therapeutics, Inc., H2 2015 71
Brain Cancer - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015 72
Brain Cancer - Pipeline by Tocagen Inc., H2 2015 73
Brain Cancer - Pipeline by ViraTherapeutics GmbH, H2 2015 74
Brain Cancer - Pipeline by Zymeworks Inc., H2 2015 75
Assessment by Monotherapy Products, H2 2015 76
Assessment by Combination Products, H2 2015 77
Number of Products by Stage and Target, H2 2015 79
Number of Products by Stage and Mechanism of Action, H2 2015 83
Number of Products by Stage and Route of Administration, H2 2015 86
Number of Products by Stage and Molecule Type, H2 2015 88
Brain Cancer Therapeutics - Recent Pipeline Updates, H2 2015 210
Brain Cancer - Dormant Projects, H2 2015 296
Brain Cancer - Dormant Projects (Contd..1), H2 2015 297
Brain Cancer - Dormant Projects (Contd..2), H2 2015 298
Brain Cancer - Dormant Projects (Contd..3), H2 2015 299
Brain Cancer - Discontinued Products, H2 2015 300